This video shows a bladder cancer surgery procedure (Transurethral Resection of Bladder Tumor (TURBT) performed with Blue Light as adjunct to White Light Cystoscopy. With courtesy of Maximillian Burger, Germany
Use of flexible Blue Light Cystoscopy at the first follow-up after TURBT* reduced the risk of tumor recurrence by 33% compared to white light alone. Randomized controlled multi-center study with 699 bladder cancer patients presented at Danish Urological Society meeting.
Oslo, Norway, 7 November 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 42% in local currency for the U.S. market in the third quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 51.1 million (Q3 2018: NOK 43.5) and an EBITDA of NOK 8.3 million (NOK -3.1 million). The company entered into a license agreement with Asieris for the global commercialization of Cevira® and reiterates the significant revenue growth and profit opportunities in the U.S. market.